Olema Oncology to Participate in Upcoming Investor Conferences
Globe Newswire•02/11/2026•16:30 ET
0
Key Highlights
- ➤Olema to participate in four investor conferences from November 10-18, 2026
- ➤Palazestrant currently advancing in two Phase 3 clinical trials
- ➤OP-3136 currently in a Phase 1 clinical study
SAN FRANCISCO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
Guggenheim 3rd Annual Healthcare Innovation Conference Date and Time: November 10, 2026 at 10 a.m. ET Format: Fireside Chat Location: Boston, MA
Get started
Create a free account to read the full story.